2024-01-30 16:40:26 ET
More on Johnson & Johnson
- Johnson & Johnson: Positioned To Receive Benefits Of Heavy R&D Investments
- Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy'
- Johnson & Johnson 2023 Q4 - Results - Earnings Call Presentation
- Johnson & Johnson inks ~$150M deal with Washington State to settle opioid claims
- J&J may pay $700M to settle state AG probe into talcum powder marketing
Read the full article on Seeking Alpha
For further details see:
J&J seeks expanded FDA approval of Darzalex Faspro for multiple myeloma